Although anthracyclines are among the most widely used chemotherapeutic agents, their therapeutic potential is limited by their extensive adverse event profile, ranging from mild to severe. The incidence rates of these reactions, however, are largely unknown.

**Mild**

- Chills - Rapid

- Urticaria - Rapid

- Pruritis - Rapid

- Injection site reaction - Rapid

- Rash -  Early

- Infection -  Early

- Nausea and vomiting -  Early

- Fever -  Early

- Diarrhea -  Early

- Abdominal pain -  Early

- Urine discoloration -  Early

- Lacrimation -  Early

- Malaise -  Early

- Anorexia - Delayed

- Photosensitivity - Delayed

- Nail discoloration - Delayed

- Skin hyperpigmentation - Delayed

- Amenorrhea - Delayed

- Oligospermia - Delayed

- Azoospermia - Delayed

- Gonadal suppression - Delayed

- Spermatogenesis inhibition - Delayed

- Asthenia - Delayed

- Co-enzyme Q10 deficiency - Delayed

**Moderate**

- Bleeding - Early

- Bone marrow suppression - Delayed

- Neutropenia - Delayed

- Dehydration - Delayed

- Stomatitis - Delayed

- Esophagitis - Delayed

- Colitis - Delayed

- Erythema - Delayed

- Palmar-plantar erythrodysesthesia - Delayed

- Conjunctivitis - Delayed

- Phlebitis - Delayed

- Skin ulcer - Delayed

- Radiation recall reaction - Delayed

- Skin ulcer - Delayed

- Elevated hepatic enzymes - Delayed

- Peripheral neuropathy - Delayed

**Severe**

- Anaphylactoid reactions - Rapid

- Tissue necrosis - Early

- Coma - Early

- Leukopenia - Delayed

- Thrombocytopenia - Delayed

- Heart Failure - Delayed

- Cardiomyopathy - Delayed

- Cardiotoxicity - Delayed

- Pericarditis - Delayed

- Myocarditis - Delayed

- Typhlitis - Delayed

- Peptic ulcer - Delayed

- GI bleeding - Delayed

- Keratitis - Delayed

- Tumor lysis syndrome - Delayed

- New primary malignancy - Delayed

- Seizures - Delayed

Researchers are studying ways to mitigate the toxicity of anthracyclines through newer technologies, including nanoparticle delivery systems.